Monday's Health Winners & Losers

Acorda Therapeutics(ACOR) saw its shares soar after the company reported positive results from a late-stage clinical trial of its multiple sclerosis drug Fampridine-SR. The trial dealt with how the drug could advance the walking abilities of MS patients.

Acorda said the findings of three separate criteria were statistically significant. Shares of Acorda more than tripled, rising 243% to $7.62.

GPC Biotech(GPCB) and Pharmion(PHRM) were higher after a late-stage trial produced hopeful results.

GPC said certain previously treated patients with prostate cancer taking the company's lead product candidate satraplatin plus prednisone saw a 40% reduction in the risk of disease progression compared with those on a placebo and prednisone. GPC rose 35.7% to $19, and Pharmion was up 18.8% to $21.40.

Orchid Cellmark(ORCH) won contracts with the London, Kent and Sussex police forces, worth a combined $3.5 million a year, sending its shares 4.7% higher to $2.45.

Among other movers were Vertex Pharmaceuticals(VRTX), up 1% to $32, and Usana Health Sciences(USNA), up 1.5% to $45.99. Medtronic(MDT) fell 1% to $46.12, Celgene(CELG) lost 1.9% to $41.19, and Genzyme(GENZ) dipped 1.1% to $64.86.

InterMune(ITMN) was 1.6% lower to $16.50, St. Jude Medical(STJ) fell 3.1% to $34.51, Tercica(TRCA) sank 2.5% to $4.94, Hi-Tech Pharmacal(HITK) was off 2% to $13.58, and Caraco Pharmaceutical Laboratories(CPD) lost 1.6% to $10.47.

>To order reprints of this article, click here: Reprints